Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Axsome Therapeutics Stock Quote

Axsome Therapeutics (NASDAQ: AXSM)

Price as of May 24, 2024, 2:53 p.m. ET

Axsome Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
AXSM +7.93% +199.96% +24.55% +749%
S&P +28.01% +86.40% +13.26% +153%

Axsome Therapeutics Company Info

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

News & Analysis

The Fool has written over 200 articles on Axsome Therapeutics.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.